These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 28588021)

  • 1. Accelerometer-Measured Daily Activity in Heart Failure With Preserved Ejection Fraction: Clinical Correlates and Association With Standard Heart Failure Severity Indices.
    Snipelisky D; Kelly J; Levine JA; Koepp GA; Anstrom KJ; McNulty SE; Zakeri R; Felker GM; Hernandez AF; Braunwald E; Redfield MM
    Circ Heart Fail; 2017 Jun; 10(6):e003878. PubMed ID: 28588021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction.
    Redfield MM; Anstrom KJ; Levine JA; Koepp GA; Borlaug BA; Chen HH; LeWinter MM; Joseph SM; Shah SJ; Semigran MJ; Felker GM; Cole RT; Reeves GR; Tedford RJ; Tang WH; McNulty SE; Velazquez EJ; Shah MR; Braunwald E;
    N Engl J Med; 2015 Dec; 373(24):2314-24. PubMed ID: 26549714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physical Activity, Quality of Life, and Biomarkers in Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction (from the NEAT-HFpEF Trial).
    Patel RB; Vaduganathan M; Felker GM; Butler J; Redfield MM; Shah SJ
    Am J Cardiol; 2019 May; 123(10):1660-1666. PubMed ID: 30876658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in heart failure with preserved ejection fraction: importance of obesity, functional capacity, and physical inactivity.
    Reddy YNV; Rikhi A; Obokata M; Shah SJ; Lewis GD; AbouEzzedine OF; Dunlay S; McNulty S; Chakraborty H; Stevenson LW; Redfield MM; Borlaug BA
    Eur J Heart Fail; 2020 Jun; 22(6):1009-1018. PubMed ID: 32150314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
    Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
    Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).
    Kristensen SL; Mogensen UM; Jhund PS; Petrie MC; Preiss D; Win S; Køber L; McKelvie RS; Zile MR; Anand IS; Komajda M; Gottdiener JS; Carson PE; McMurray JJ
    Circulation; 2017 Feb; 135(8):724-735. PubMed ID: 28052977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atrial Fibrillation and Semaglutide Effects in Obesity-Related Heart Failure With Preserved Ejection Fraction: STEP-HFpEF Program.
    Verma S; Butler J; Borlaug BA; Davies MJ; Kitzman DW; Petrie MC; Shah SJ; Jensen TJ; Rasmussen S; Rönnbäck C; Merkely B; O'Keefe E; Kosiborod MN;
    J Am Coll Cardiol; 2024 Oct; 84(17):1603-1614. PubMed ID: 39217565
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigating a biomarker-driven approach to target collagen turnover in diabetic heart failure with preserved ejection fraction patients. Effect of torasemide versus furosemide on serum C-terminal propeptide of procollagen type I (DROP-PIP trial).
    Trippel TD; Van Linthout S; Westermann D; Lindhorst R; Sandek A; Ernst S; Bobenko A; Kasner M; Spillmann F; González A; López B; Ravassa S; Pieske B; Paulus WJ; Díez J; Edelmann F; Tschöpe C
    Eur J Heart Fail; 2018 Mar; 20(3):460-470. PubMed ID: 28891228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
    Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physical activity measured with implanted devices predicts patient outcome in chronic heart failure.
    Conraads VM; Spruit MA; Braunschweig F; Cowie MR; Tavazzi L; Borggrefe M; Hill MR; Jacobs S; Gerritse B; van Veldhuisen DJ
    Circ Heart Fail; 2014 Mar; 7(2):279-87. PubMed ID: 24519908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction: A Holistic Proteomic Approach.
    Hage C; Michaëlsson E; Linde C; Donal E; Daubert JC; Gan LM; Lund LH
    Circ Cardiovasc Genet; 2017 Feb; 10(1):. PubMed ID: 28100627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
    McKelvie RS; Komajda M; McMurray J; Zile M; Ptaszynska A; Donovan M; Carson P; Massie BM;
    J Card Fail; 2010 Feb; 16(2):128-34. PubMed ID: 20142024
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
    Armstrong PW; Lam CSP; Anstrom KJ; Ezekowitz J; Hernandez AF; O'Connor CM; Pieske B; Ponikowski P; Shah SJ; Solomon SD; Voors AA; She L; Vlajnic V; Carvalho F; Bamber L; Blaustein RO; Roessig L; Butler J;
    JAMA; 2020 Oct; 324(15):1512-1521. PubMed ID: 33079152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifestyle Walking Intervention for Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial.
    Vetrovsky T; Siranec M; Frybova T; Gant I; Svobodova I; Linhart A; Parenica J; Miklikova M; Sujakova L; Pospisil D; Pelouch R; Odrazkova D; Parizek P; Precek J; Hutyra M; Taborsky M; Vesely J; Griva M; Semerad M; Bunc V; Hrabcova K; Vojkuvkova A; Svoboda M; Belohlavek J;
    Circulation; 2024 Jan; 149(3):177-188. PubMed ID: 37955615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
    Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
    Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study.
    Pieske B; Maggioni AP; Lam CSP; Pieske-Kraigher E; Filippatos G; Butler J; Ponikowski P; Shah SJ; Solomon SD; Scalise AV; Mueller K; Roessig L; Gheorghiade M
    Eur Heart J; 2017 Apr; 38(15):1119-1127. PubMed ID: 28369340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exercise Stress Real-Time Cardiac Magnetic Resonance Imaging for Noninvasive Characterization of Heart Failure With Preserved Ejection Fraction: The HFpEF-Stress Trial.
    Backhaus SJ; Lange T; George EF; Hellenkamp K; Gertz RJ; Billing M; Wachter R; Steinmetz M; Kutty S; Raaz U; Lotz J; Friede T; Uecker M; Hasenfuß G; Seidler T; Schuster A
    Circulation; 2021 Apr; 143(15):1484-1498. PubMed ID: 33472397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IL-1 Blockade in Patients With Heart Failure With Preserved Ejection Fraction.
    Van Tassell BW; Trankle CR; Canada JM; Carbone S; Buckley L; Kadariya D; Del Buono MG; Billingsley H; Wohlford G; Viscusi M; Oddi-Erdle C; Abouzaki NA; Dixon D; Biondi-Zoccai G; Arena R; Abbate A
    Circ Heart Fail; 2018 Aug; 11(8):e005036. PubMed ID: 30354558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-6 in Patients With Heart Failure and Preserved Ejection Fraction.
    Alogna A; Koepp KE; Sabbah M; Espindola Netto JM; Jensen MD; Kirkland JL; Lam CSP; Obokata M; Petrie MC; Ridker PM; Sorimachi H; Tchkonia T; Voors A; Redfield MM; Borlaug BA
    JACC Heart Fail; 2023 Nov; 11(11):1549-1561. PubMed ID: 37565977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.